Abnormally Expressed lncRNAs as Potential Biomarkers for Gastric Cancer Risk: A Diagnostic Meta-Bioinformatics Analysis

Table 2

Diagnostic performance of lncRNAs.

Subgroups	Number	Pooled SEN (95% CI)	test (%) SEN	Pooled SPE (95% CI)	test (%) SPE	Pooled PLR (95% CI)	test (%) PLR	Pooled NLR (95% CI)	test (%) NLR	Pooled DOR (95% CI)	test (%) DOR	AUC (95% CI)		value
All studies	54	0.71 (0.67, 0.74)	84.23	0.76 (0.71, 0.79)	89.04	2.9 (2.5, 3.4)	83.95	0.39 (0.34, 0.43)	80.61	8 (6, 10)	78.9	0.79 (0.75, 0.82)
Location
Intergenic	22	0.72 (0.66, 0.77)	85.33	0.78 (0.72, 0.83)	88.42	3.2 (2.5, 4.1)	79.22	0.36 (0.30, 0.44)	83.17	9 (6, 13)	78.2	0.81 (0.78, 0.84)	-0.076	0.939
Antisense	11	0.73 (0.66, 0.79)	82.51	0.71 (0.61, 0.80)	90.08	2.6 (1.9, 3.4)	85.94	0.38 (0.30, 0.47)	74.65	7 (4, 10)	71	0.78 (0.75, 0.82)
Sample type
Circulating	19	0.76 (0.71, 0.81)	84.34	0.79 (0.71, 0.86)	92.98	3.7 (2.6, 5.3)	91.66	0.3 (0.24, 0.37)	83.61	12 (7, 20)	85	0.84 (0.80, 0.87)	-2.582	0.01
Tissue	32	0.69 (0.65, 0.73)	82.38	0.72 (0.68, 0.76)	83.41	2.5 (2.2, 2.9)	68.05	0.42 (0.38, 0.48)	75.4	6 (5, 7)	72.2	0.77 (0.73, 0.80)
Sample size
≤200	35	0.68 (0.63, 0.72)	79.78	0.75 (0.69, 0.79)	87.69	2.7 (2.2, 3.2)	77.63	0.43 (0.39, 0.48)	65.02	6 (5, 8)	57.3	0.76 (0.72, 0.80)	-1.259	0.208
>200	19	0.75 (0.70, 0.80)	87.58	0.77 (0.71, 0.82)	91.38	3.2 (2.5, 4.2)	87.41	0.33 (0.26, 0.41)	88.07	10 (6, 15)	88.2	0.82 (0.79, 0.86)
Quality
	16	0.71 (0.65, 0.77)	81.76	0.75 (0.64, 0.83)	92.36	2.8 (2.0, 4.0)	87.66	0.38 (0.31, 0.47)	72.18	7 (5, 12)	80	0.78 (0.74, 0.82)	-0.303	0.762
	38	0.71 (0.66, 0.75)	85.42	0.76 (0.72, 0.80)	86.63	3.0 (2.5, 3.5)	77.38	0.39 (0.34, 0.44)	83.21	8 (6, 10)	78.9	0.80 (0.76, 0.83)

value: -test testing the between-subgroup AUC differences.